Trial Profile
Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary) ; Rilotumumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MEGA
- 13 Nov 2020 Status changed from active, no longer recruiting to completed.
- 23 May 2019 Results (n=162) published in the European Journal of Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.